Nanobiotix announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M milestone payment from strategic partner Janssen Pharmaceutica, a Johnson & Johnson (JNJ) company. This $20M represents the first applicable development milestone from the global licensing agreement executed between Nanobiotix and Janssen.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NBTX:
- Voting Rights and Shares Capital of the Company
- Nanobiotix says LianBio enters NBTXR3 development pact with Johnson & Johnson
- Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
- Nanobiotix initiated with an Outperform at Leerink
- Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.